Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-α in a phase III trial: Final results and geographical analysis Academic Article uri icon

Overview

MeSH Major

  • Carcinoma, Renal Cell
  • Indoles
  • Interferon-alpha
  • Kidney Neoplasms
  • Pyrroles
  • Quality of Life

abstract

  • Patients treated with sunitinib in this study had improved HRQoL, compared with patients treated with IFN-alpha. Treatment differences within the US cohort did not differ from those within the EU cohort.

publication date

  • February 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC2837567

Digital Object Identifier (DOI)

  • 10.1038/sj.bjc.6605552

PubMed ID

  • 20104222

Additional Document Info

start page

  • 658

end page

  • 64

volume

  • 102

number

  • 4